Artificial Intelligence in Type 1 Diabetes Management: A Scoping Review of Randomised Controlled Trials
Authors' conclusion
Future research should prioritise larger, longer-term real-world evaluations that use standardised safety endpoints and patient-centred outcomes, including in low- and middle-income countries to support equitable implementation.
Study context
- Population
- People with T1D using AI-based diabetes management tools; RCTs from PubMed, CINAHL and Web of Science up to January 2026
Methodological detailsPRISMA-ScR guidelines
- PRISMA-ScR guidelines
Primary result
As reported in the abstract
Clinical utility of AI-based diabetes management tools
- Evidence base small and concentrated in high-income settings
- Most trials assessed clinical utility using CGM outcomes, with mixed improvements across interventions
Safety
- No serious safety events reported; small sample sizes, short follow-up and inconsistent safety reporting limit confidence
Original publication
Artificial Intelligence in Type 1 Diabetes Management: A Scoping Review of Randomised Controlled Trials. Diabetes Obes Metab. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →